v3.26.1
Condensed Statements of Changes in Consolidated Shareholders' Equity
$ in Thousands, € in Millions
USD ($)
shares
Subsequent Investment Agreement [Member]
USD ($)
Calyxt Inc [Member]
USD ($)
Cellectis, Inc. [Member]
USD ($)
Share Capital Ordinary Shares [member]
shares
Preferrence Shares [Member]
shares
Issued capital [member]
USD ($)
Issued capital [member]
Share Capital Ordinary Shares [member]
USD ($)
Issued capital [member]
Preferrence Shares [Member]
USD ($)
Premiums Related to Share Capital [member]
USD ($)
Premiums Related to Share Capital [member]
EUR (€)
Premiums Related to Share Capital [member]
Subsequent Investment Agreement [Member]
USD ($)
Premiums Related to Share Capital [member]
Cellectis, Inc. [Member]
USD ($)
Currency Translation Adjustment [member]
USD ($)
Currency Translation Adjustment [member]
Calyxt Inc [Member]
USD ($)
Retained Earnings (Deficit) [member]
USD ($)
Retained Earnings (Deficit) [member]
Calyxt Inc [Member]
USD ($)
Income (loss) [member]
USD ($)
Attributable to Shareholders of Cellectis [member]
USD ($)
Attributable to Shareholders of Cellectis [member]
Subsequent Investment Agreement [Member]
USD ($)
Attributable to Shareholders of Cellectis [member]
Calyxt Inc [Member]
USD ($)
Attributable to Shareholders of Cellectis [member]
Cellectis, Inc. [Member]
USD ($)
Non controlling Interests [member]
USD ($)
Non controlling Interests [member]
Calyxt Inc [Member]
USD ($)
Beginning balance at Dec. 31, 2022 $ 125,941           $ 2,955     $ 583,122       $ (28,605)   $ (333,365)   $ (106,139) $ 117,968       $ 7,973  
Beginning balance, shares at Dec. 31, 2022 | shares         45,675,968                                      
Net income (loss) (108,443)                                 (101,059) (101,059)       (7,384)  
Other comprehensive income (loss) 1,994                         (73)   597     524       1,470  
Total Comprehensive income (loss) (106,449)                         (73)   597   (101,059) (100,535)       (5,914)  
Allocation of prior period loss                               (106,139)   106,139            
Capital increase 69,985             $ 1,401 $ 1,401 68,584                 69,985          
Capital increase, Shares | shares         25,907,800                                      
Transaction costs related to capital increase       $ (2,049)           (2,049)     $ (2,049)                 $ (2,049)    
Operation between shareholders                               343     343       (343)  
Loss of control over Calyxt     $ (3,625)                                         $ (3,625)
OCI Reclassification pursuant to Calyxt's deconsolidation     $ (8,022)                       $ (8,012)   $ (10)       $ (8,022)      
Exercise of share warrants, employee warrants, stock-options and free-shares vesting, amount $ 9           9 9                     9          
Exercise of share warrants, employee warrants, stock-options and free-shares vesting, shares | shares 167,433       167,433                                      
Non-cash stock-based compensation expense $ 9,092                 7,086                 7,086       2,006  
Other movements (187)                 (133,958)           133,868     (90)       (97)  
Balance at end of year at Dec. 31, 2023 84,695           4,365     522,785       (36,690)   (304,707)   (101,059) 84,695       0  
Ending balance, shares at Dec. 31, 2023 | shares         71,751,201                                      
Net income (loss) (36,761)                                 (36,761) (36,761)          
Other comprehensive income (loss) (2,811)                         (2,848)   37     (2,811)       (0)  
Total Comprehensive income (loss) (39,572)                         (2,848)   37   (36,761) (39,572)       (0)  
Allocation of prior period loss                   (112,911)           11,852   101,059            
Capital increase 140,000           1,505   $ 1,505 138,495                 140,000          
Capital increase, Shares | shares           28,000,000                                    
Transaction costs related to capital increase (207)                 (207)                 (207)          
Derecognition of AZ SIA derivative   $ (56,970)               (56,970)   $ (56,970)               $ (56,970)        
Exercise of share warrants, employee warrants, stock-options and free-shares vesting, amount $ 0           19 19   9           (27)     0          
Exercise of share warrants, employee warrants, stock-options and free-shares vesting, shares | shares 342,672       342,672                                      
Non-cash stock-based compensation expense $ 3,167                 3,167                 3,167          
Other movements (79)                 (79)                 (79)          
Balance at end of year at Dec. 31, 2024 131,033           5,889     494,288       (39,537)   (292,846)   (36,761) 131,033       0  
Ending balance, shares at Dec. 31, 2024 | shares         72,093,873 28,000,000                                    
Net income (loss) (67,593)                                 (67,593) (67,593)          
Other comprehensive income (loss) 6,307                         6,221   86     6,307          
Total Comprehensive income (loss) (61,286)                         6,221   86   (67,593) (61,286)          
Allocation of prior period loss                   (62,999) [1] € (58.2)         26,239   36,761            
Exercise of share warrants, employee warrants, stock-options and free-shares vesting, amount $ 33           14 [2] $ 14   36 [2]           (16)     33          
Exercise of share warrants, employee warrants, stock-options and free-shares vesting, shares | shares 245,568 [2]       245,568                                      
Non-cash stock-based compensation expense $ 6,110                 6,110                 6,110          
Other movements 11                 11                 11          
Balance at end of year at Dec. 31, 2025 $ 75,901           $ 5,903     $ 437,445       $ (33,316)   $ (266,538)   $ (67,593) $ 75,901       $ 0  
Ending balance, shares at Dec. 31, 2025 | shares         72,339,441 28,000,000                                    
[1] The standalone statutory loss for the year ended December 31, 2024 of the parent company was allocated to premiums related to share capital for 58.2 million euros or approximately $63.0 million following the decision of the Annual General Meeting of shareholders which took place on June 26, 2025. The difference between this standalone statutory loss of the parent company and the consolidated net loss was allocated to retained deficit for $26.2 million.
[2] During the year ended December 31, 2025, 245,568 ordinary shares were issued to the benefit of Company's employees related to the free shares plans which met vesting conditions and exercised stock options.